Bio-Rad Laboratories, Inc., manufacturer and distributor of life science research and clinical diagnostic products, has purchased GnuBIO, Inc. Based in Cambridge, MA, GnuBIO is developing a fast and fully integrated droplet-based DNA sequencing technology that incorporates all the functions of DNA sequencing into a single, integrated workflow for medical diagnostics as well as research markets. According to company representatives, this sequencing technology does not require separate workflows for target selection, DNA amplification, DNA sequencing and analysis, but rather will integrate the entire workflow into a single, low-cost solution that produces results within hours.
“We are pleased to have GnuBIO join Bio-Rad,” says Norman Schwartz, Bio-Rad President and CEO. “We believe GnuBIO's innovative DNA workflow is well-suited for the clinical diagnostics sequencing market and will leverage Bio-Rad's leadership role in the area of droplet digital PCR.” Learn more about GnuBIO.
Read more
